AUPH
Aurinia Pharmaceuticals Inc.
$14.17
0.2
(1.43%)
| Exchange: | |
| Market Cap: | 1.868B |
| Shares Outstanding: | 485714 |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Peter S. Greenleaf | |||||
| Full Time Employees: | 130 | |||||
| Address: |
|
|||||
| Website: | https://www.auriniapharma.com |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
